Overview

A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome

Status:
Completed
Trial end date:
2017-07-06
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety, tolerability, and pharmacodynamic activity of ADX-102 Ophthalmic Solutions and ADX-102 Ophthalmic Lipid Solution in subjects with dry eye syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
Aldeyra Therapeutics, Inc.
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions